In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...
Read MoreEvaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.
In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....
Read MoreEvaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.
In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...
Read MoreComparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer
In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...
Read MoreCan the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?
In a nutshell This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients. Some...
Read More